Grant Hesser

Credit Suisse issued a report on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and initiated coverage on the company due to strength seen in their drug pipeline. Credit Suisse rates BioMarin as Outperform with a $110 price target. Analysts Alethia Young, Eliana Merle and Grant Hesser highlighted...